Nifty500 Healthcare's PB is more expensive than 81% of the last year.
Not enough history for a 5Y percentile, showing 1Y instead.
The Nifty500 Healthcare PE ratio is 49.50 as of 19 November 2026, about 18% above its 1-year median of 41.89, which places it in moderately overvalued territory on a historical basis.
| Period | Median PE | Current vs Median |
|---|---|---|
| 1 Year | 41.89 | +18.18% |
Series start. P/E is published from 24 Jun 2025. Index values go back to 1 Apr 2005.
Index earnings are the profits behind the index level: the closing value divided by the P/E ratio, in index points. The line moves in steps because it changes only when trailing four-quarter profits are updated or the constituents change. Compare it with price to see whether a move came from earnings or from a change in what investors pay for them.
Nifty500 Healthcare earnings grew -6.11% a year over the last 1 year, while the index moved +18.64% a year and its P/E went from 39.2 to 49.5.
Earnings growth is annualised from the last trading day at or before the start of each window to 19 Nov 2026. Price growth uses the index level over the same two dates, excluding dividends. EPS is undefined on days with no published P/E, so those days are skipped. Past growth, not a forecast.
1 ETF and 0 index funds track this index. Prices and NAVs as of 18 Nov 2026.
| ETF | Symbol | Price | NAV | Premium | 1Y |
|---|---|---|---|---|---|
| Mirae Asset Nifty 500 Healthcare ETF | HEALTHCARE | 22.5 | - | - | - |
Listed for information only, not a recommendation. Check expense ratio and tracking difference before investing.
View full performance and risk
Returns as of October 2026, from the NSE factsheet for the Nifty500 Healthcare. 1-year returns are absolute; 5-year returns are annualized.
The Nifty500 Healthcare contains 44 constituents.
11 October 2026: Added Acutaas Chemicals Ltd., Anthem Biosciences Ltd., Onesource Specialty Pharma Ltd., Rubicon Research Ltd., Wockhardt Ltd.. Removed Alembic Pharmaceuticals Ltd., Alivus Life Sciences Ltd., AstraZenca Pharma India Ltd., Eris Lifesciences Ltd., Indegene Ltd., J.B. Chemicals & Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Metropolis Healthcare Ltd., Pfizer Ltd..
Constituent list as of 15 November 2026, sourced from NSE Indices. Weights as of 30 October 2026, from the NSE factsheet.
Summarised from NSE's official methodology document (PDF) for the Nifty500 Healthcare; the PDF is authoritative.
Get weekly market insights and valuation updates delivered to your inbox.
As of 19 November 2026, the Nifty500 Healthcare PE ratio is 49.50. That is about 18% above its 1-year median of 41.89.
On a historical basis it screens as moderately overvalued. Its current PE of 49.50 sits above every median window: 1-year (41.89).
Over the past one year its median PE has been 41.89, and over the past six months 45.31. Today's 49.50 is toward the upper end of that historical range.
The Nifty500 Healthcare contains 44 stocks. By number of companies, its largest sectors are Healthcare (44 stocks).
As of October 2026, the Nifty500 Healthcare total return (with dividends reinvested) is +13.43% over the past year and +14.72% annualized over the past five years. One-year figures are absolute; multi-year figures are annualized (CAGR). Data from the NSE factsheet.
Over the year to October 2026, the Nifty500 Healthcare had an annualized volatility (standard deviation of daily returns) of 13.78%. Its beta versus the Nifty 50 is 0.56, meaning it has moved less than the broad market.
Nifty500 Healthcare earnings, measured as the index level divided by its P/E, grew -6.11% a year over the last 1 year, while the index itself moved +18.64% a year and its P/E rose from 39.18 to 49.50. Past growth, not a forecast.
The Nifty500 Healthcare is rebalanced quarterly. Details are in the official NSE methodology document.
Last updated: 19 November 2026.